Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT05429268 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT05429268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05429268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Lead sponsor
Incyte Corporation
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 23, 2022
Completion date
April 1, 2027
Enrollment
82 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, large b-cell lymphoma